Article

ISTA Pharmaceuticals reaches funding agreement

ISTA Pharmaceuticals, Inc. has entered into an agreement with Deerfield Management, Sprout, and Sanderling Ventures, three of its long-term shareholders, to provide it with up to $65 million in financing through a flexible credit facility.

Key Points

Irvine, CA-ISTA Pharmaceuticals, Inc. has entered into an agreement with Deerfield Management, Sprout, and Sanderling Ventures, three of its long-term shareholders, to provide it with up to $65 million in financing through a flexible credit facility.

"Deerfield, Sanderling, and Sprout are leading health care investors and also three of ISTA's largest investors, and we appreciate their continued funding of ISTA's growth," said Vicente Anido Jr., PhD, president and chief executive officer of ISTA Pharmaceuticals. "This $65 million facility is the culmination of 5 months of assessing our business and strategic options.

"Our goal was to ensure we could flexibly fund ISTA's future growth while minimizing dilution impact on our shareholders. We fully believe these corporate finance activities have the potential to give our shareholders the best potential return on their investment."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
© 2025 MJH Life Sciences

All rights reserved.